Small Molecules, Big Expectations: How CDMOs Are Helping Sponsors Navigate Complexity, Speed, Scale-Up, and Sustainability

Small molecules continue to play a major part in pharmaceutical development, but increasing molecular complexity, accelerated timelines, and evolving manufacturing and regulatory requirements are creating new challenges for the industry.In this GEN Podcast – part 2 in a 3-part series -- a trio of experts from SK Pharmteco discuss how CDMOs are helping biopharma companies navigate critical areas including scale-up, technology transfer, advanced manufacturing, automation, sustainability, the emergence of AI, and supply chain reliability. The discussion explores practical strategies for improving development efficiency while supporting quality, scalability, and long-term commercial success.Guest SpeakersSteve Barr, PhD -- Head of Small Molecule Business Unit and VP Global Alliances, SK Pharmteco.Darryl Ratty -- Executive Director of Global ESG (Environmental, Social and Governance), SK Pharmteco.Bill Dubay -- VP, Global Research and Development, SK Pharmteco.Moderator:Kevin Davies, PhD, Editorial Director, GEN Hosted on Acast. See acast.com/privacy for more information.